Safety and efficacy of peramivir for influenza treatment

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 2017-2038

  Hata, Atsuko ^a   Akashi Ueda, Ryoko ^a   Takamatsu, Kazufumi ^a   Matsumura, Takuro ^a  

^a Kitano Hospital   (Japan)

Author keywords

Antiviral therapy; Avian flu; Drug resistance; Neuraminidase inhibitor; Pandemic; pH1N1

Indexed keywords

LANINAMIVIR; OSELTAMIVIR; PERAMIVIR; PLACEBO; SIALIDASE INHIBITOR; ZANAMIVIR; CYCLOPENTANE DERIVATIVE; GUANIDINE DERIVATIVE;

2009 H1N1 INFLUENZA; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; AVIAN INFLUENZA VIRUS; BRONCHOSPASM; CLINICAL TRIAL (TOPIC); CREATININE BLOOD LEVEL; CRITICALLY ILL PATIENT; DIARRHEA; DISEASE DURATION; DOSE RESPONSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; EARLY INTERVENTION; FEVER; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HIGH RISK POPULATION; HUMAN; INFLUENZA; INFLUENZA A; INFLUENZA A (H3N2); INFLUENZA B; LOADING DRUG DOSE; MENTAL DISEASE; MORTALITY; MULTICENTER STUDY (TOPIC); NAUSEA; NEUTROPHIL COUNT; NONHUMAN; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PANDEMIC; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RAPID TEST; RASH; RECOMMENDED DRUG DOSE; RESPIRATORY FAILURE; SEASONAL INFLUENZA; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; UNITED STATES; VIRAL CLEARANCE; VIRUS LOAD; VOMITING; ADVERSE DRUG REACTION; INFLUENZA, HUMAN;

CYCLOPENTANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GUANIDINES; HUMANS; INFLUENZA, HUMAN;

EID: 84908303936     PISSN: 11778881     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S46654     Document Type: Article

References (118)

1. Glezen WP. Clinical practice. Prevention and treatment of seasonal influenza. N Engl J Med. 2008;359(24):2579–2585.
2. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM; Centers for Disease Control and Prevention (CDC). Antiviral agents for the treatment and chemoprophylaxis of influenza – recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60(1):1–24.
3. Bouvier NM, Palese P. The biology of influenza viruses. Vaccine. 2008;26:D49–D53.
4. Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet. 2000;355(9206):827–835.
5. Bright RA, Medina MJ, Xu X. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet. 2005;366(9492):1175–1181.
6. Bantia S, Parker CD, Ananth SL, et al. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob Agents Chemother. 2001;45(4):1162–1167.
7. Bantia S, Arnold CS, Parker CD, Upshaw R, Chand P. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res. 2006;69(1):39–45.
8. Bautista E, Chotpitayasunondh T, Gao Z, et al; Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med. 2010;362(18):1708–1719.
9. BioCryst Pharmaceuticals. [homepage on the Internet]. Birmingham:Corporate Partnerships Available from: http://www.biocryst.com/peramivir. Accessed September 4, 2014.
10. Fever lasting for less than 34 hours in patients treated with peramivir [pamphlet]. Osaka: Shionogi & Co., Ltd.; 2013.
11. Kohno S, Yen MY, Cheong HJ, et al; S-021812 Clinical Study Group. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob Agents Chemother. 2011;55(11):5267–5276.
12. Sugaya N, Kohno S, Ishibashi T, Wajima T, Takahashi T. Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection. Antimicrob Agents Chemother. 2012;56(1):369–377.
13. BioCryst Pharmaceuticals. [homepage on the Internet]. Birmingham: BioCryst’s Partner Green Cross Receives Marketing & Manufacturing Approval for Peramivir in South Korea. Available from: http://investor.shareholder.com/biocryst/releasedetail.cfm?ReleaseID=499386. Accessed September 4, 2014.
14. Birnkrant D, Cox E. The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med. 2009;361(23): 2204–2207.
15. Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2014;4: CD008965.
16. Drusano GL, Treanor J, Fowler C, et al. RWJ-270201 rapidly clears both influenza A and B in challenge studies. III International Symposium on Respiratory Viral Infections; December 1; 2000; St.Lucia.
17. Young D, Fowler C, Bush K. RWJ-270201 (BCX-1812): a novel neuraminidase inhibitor for influenza. Philos Trans R Soc Lond B Biol Sci. 2001;356(1416):1905–1913.
18. Hayden FG, Treanor JJ, Qu R, Fowler C. Safety and efficacy of an oral neuraminidase inhibitor RWJ-270201 in treating experimental influenza A and B in healthy adult volunteers. Poster presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17–20, 2000; Toronto, Ontario. Abstract.
19. Sidwell RW, Smee DF. Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza. Expert Opin Investig Drugs. 2002;11(6): 859–869.
20. Barroso L, Treanor J, Gubareva L, Hayden FG. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment. Antivir Ther. 2005;10(8):901–910.
21. Castillo R, Holland LE, Boltz DA. Peramivir and its use in H1N1 influenza. Drugs Today (Barc). 2010;46(6):399–408.
22. Shetty AK, Peek LA. Peramivir for the treatment of influenza. Expert Rev Anti Infect Ther. 2012;10(2):123–143.
23. Kohno S, Kida H, Mizuguchi M, Shimada J; S-021812 Clinical Study Group. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother. 2010;54(11):4568–4574.
24. Ison MG, Fraiz J, Heller B, et al. Intravenous peramivir for treatment of influenza in hospitalized patients. Antivir Ther. Epub August 28, 2013.
25. Kohno S, Kida H, Mizuguchi M, et al; S-021812 Clinical Study Group. Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients. Antimicrob Agents Chemother. 2011;55(6):2803–2812.
26. Ison MG, Hui DS, Clezy K, et al. A clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adults. Antivir Ther. 2013;18(5):651–661.
27. Bennett R [webpage on the Internet]. BioCryst announces outcome from the peramivir Phase 3 interim analysis. Durham, NC: BioCryst Pharmaceuticals, Inc.; 2012. Available from: http://investor.shareholder.com/biocryst/releasedetail.cfm?ReleaseID=719562. Accessed November 7, 2012.
28. Smith SM, Gums JG. Antivirals for influenza: strategies for use in pediatrics. Paediatr Drugs. 2010;12(5):285–299.
29. Mancuso CE, Gabay MP, Steinke LM, Vanosdol SJ. Peramivir: an intravenous neuraminidase inhibitor for the treatment of 2009 H1N1 influenza. Ann Pharmacother. 2010;44(7–8):1240–1249.
30. Centers for Disease Control and Prevention. [homepage on the Internet]. Atlanta: Updated Interim Recommendations for the Use of Antiviral Medications in the Treatment and Prevention of Influenza for the 2009-2010 Season [updated 2009 December 7] Available from: http://www.cdc.gov/h1n1flu/recommendations.htm. Accessed September 4, 2014.
31. Shrestha SS, Swerdlow DL, Borse RH, et al. Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (Apr 2009–Apr 2010). Clin Infect Dis. 2011;52 Suppl 1:S75–S82.
32. Yu Y, Garg S, Yu PA, et al. Peramivir use for treatment of hospitalized patients with influenza A(H1N1)pdm09 under emergency use authorization, Oct 2009–Jun 2010. Clin Infect Dis. 2012;55(1):8–15.
33. Doshi S, Kamimoto L, Finelli L, et al. Description of antiviral treatment among adults hospitalized with influenza before and during the 2009 pandemic: United States, 2005–2009. J Infect Dis. 2011;204(12): 1848–1856.
34. Fry AM, Pérez A, Finelli L. Use of intravenous neuraminidase inhibitors during the 2009 pandemic: results from population-based surveillance. JAMA. 2011;306(2):160–162.
35. Hernandez JE, Adiga R, Armstrong R, et al; eIND Peramivir Investigators. Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States. Clin Infect Dis. 2011;52(6):695–706.
36. Jain S, Fry AM. Peramivir: another tool for influenza treatment? Clin Infect Dis. 2011;52(6):707–709.
37. Louie JK, Yang S, Yen C, Acosta M, Schechter R, Uyeki TM. Use of intravenous peramivir for treatment of severe influenza A(H1N1)pdm09. PLoS One. 2012;7(6):e40261.
38. Sorbello A, Jones SC, Carter W, et al. Emergency use authorization for intravenous peramivir: evaluation of safety in the treatment of hospitalized patients infected with 2009 H1N1 influenza A virus. Clin Infect Dis. 2012;55(1):1–7.
39. Randolph AG, Vaughn F, Sullivan R, et al; Pediatric Acute Lung Injury and Sepsis Investigator’s Network and the National Heart, Lung, and Blood Institute ARDS Clinical Trials Network. Critically ill children during the 2009–2010 influenza pandemic in the United States. Pediatrics. 2011;128(6):e1450–e1458.
40. Jouvet P, Hutchison J, Pinto R, et al. Critical illness in children with influenza A/pH1N1 2009 infection in Canada. Pediatr Crit Care Med. 2010;11(5):603–609.
41. The ANZIC Influenza Investigators. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med. 2009;361(20):1925–1934.
42. Farias JA, Fernandez A, Monteverde E, et al. Critically ill infants and children with influenza A (H1N1) in pediatric intensive care units in Argentina. Intensive Care Med. 2010;36(6):1015–1022.
43. Louie JK, Yang S, Samuel MC, Uyeki TM, Schechter R. Neuraminidase inhibitors for critically ill children with influenza. Pediatrics. 2013; 132(6):e1539–e1545.
44. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA. 2000;283(8):1016–1024.
45. Urushihara H, Matsui S, Kawakami K. Emergency authorization of medical products: regulatory challenges from the 2009 H1N1 influenza pandemic in Japan. Biosecur Bioterror. 2012;10(4):372–382.
46. Tominaga T, Ando Y, Nagai N, Sato J, Kondo T. Balancing societal needs and regulatory certainty: the case study of peramivir in Japan. Clin Pharmacol Ther. 2013;93(4):342–344.
47. Takemoto Y, Asai T, Ikezoe I, et al. Clinical Effects of Oseltamivir, Zanamivir, Laninamivir and Peramivir on Seasonal Influenza Infection in Outpatients in Japan during the Winter of 2012–2013. Chemotherapy. 2013;59(5):373–378.
48. Shobugawa Y, Saito R, Sato I, et al. Clinical effectiveness of neuraminidase inhibitors – oseltamivir, zanamivir, laninamivir, and peramivir – for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010–2011 influenza season in Japan. J Infect Chemother. 2012;18(6):858–864.
49. Hikita T, Hikita H, Hikita F, Hikita N, Hikita S. Clinical effectiveness of peramivir in comparison with other neuraminidase inhibitors in pediatric influenza patients. Int J Pediatr. 2012;2012:834181.
50. Yoshino Y, Seo K, Koga I, Kitazawa T, Ota Y. Clinical efficacy of peramivir in adult patients with seasonal influenza during the winter of 2012 in Japan. Clin Respir J. Epub March 10, 2014.
51. Donner B, Bader-Weder S, Schwarz R, Peng MM, Smith JR, Niranjan V. Safety profile of oseltamivir during the 2009 influenza pandemic. Pharmacoepidemiol Drug Saf. 2011;20(5):532–543.
52. Michiels B, Van Puyenbroeck K, Verhoeven V, Vermeire E, Coenen S. The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews. PLoS One. 2013;8(4):e60348.
53. Burch J, Paulden M, Conti S, et al. Antiviral drugs for the treatment of influenza: a systematic review and economic evaluation. Health Technol Assess. 2009;13(58):1–265, iii–iv.
54. Relenza dear doctor letter in EU follows US advisory. In: “The Pink Sheet” F-D-C Reports. Chevy Chase, MD: 2000.
55. Williamson JC, Pegram PS. Respiratory distress associated with zanamivir. N Engl J Med. 2000;342(9):661–662.
56. Wang K, Shun-Shin M, Gill P, et al. Neuraminidase inhibitors for preventing and treating influenza in children. Cochrane Database Syst Rev. 2012;1:CD002744.
57. Okumura A, Kubota T, Kato T, Morishima T. Oseltamivir and delirious behavior in children with influenza. Pediatr Infect Dis J. 2006;25(6):572.
58. Toovey S, Rayner C, Prinssen E, et al. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saf. 2008;31(12):1097–1114.
59. Hama R. Oseltamivir’s adverse reactions: fifty sudden deaths may be related to central suppression. BMJ. 2007;335(7610):59.
60. ® (oseltamivir phosphate) [prescribing information]. South San Francisco, CA: Genentech, Inc.; 2012. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021087s057lbl.pdf. Accessed September 4, 2014.
61. Shin JH, Kim BY, Park HR, Kim SW, Kim SW. The effect of pneumococcal polysaccharide vaccine in a mouse model of allergic rhinitis. Otolaryngol Head Neck Surg. 2013;148(3):383–390.
62. United States Food and Drug Administration. Emergency Use Authorization of Peramivir IV Fact Sheet for Health Care Providers. White Oak, MD: United States Food and Drug Administration; 2009. Available from: Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInormationforPatientsandProviders/UCM187811.pdf.
63. McKimm-Breschkin JL. Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance. Influenza Other Respir Viruses. 2013;7 Suppl 1:25–36.
64. Centers for Disease Control and Prevention [webpage on the Internet]. Influenza antiviral drug resistance: questions and answers. Atlanta, GA; 2014. Available from: http://www.cdc.gov/flu/about/qa/antiviralresistance.htm. Accessed February 28, 2014.
65. Gubareva LV, Webster RG, Hayden FG. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Chemother. 2001;45(12):3403–3408.
66. Gubareva LV, Kaiser L, Matrosovich MN, et al. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis. 2001;183(4):523–31.
67. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet. 2004;364(9436):759–65.
68. Ward P, Small I, Smith J, et al. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother. 2005;55(Suppl. 1):i5–21.
69. Stephenson I, Democratis J, Lackenby A, et al. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. Clin Infect Dis. 2009;48(4):389–96.
70. Weinstock DM, Gubareva LV, Zuccotti G. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. New Engl J. 2003;348(9):867–8.
71. Renaud C, Kuypers J, Englund JA. Emerging oseltamivir resistance in seasonal and pandemic influenza A/H1N1. J Clin Virol. 2011;52(2):70–78.
72. Ujike M, Shimabukuro K, Mochizuki K, Obuchi M, Kageyama T, Shirakura M, et al. Oseltamivir-resistant influenza viruses A (H1N1) during 2007–2009 influenza seasons, Japan. Emerg Infect Dis. 2010;16 (6):926–35.
73. Hauge SH, Dudman S, Borgen K, Lackenby A, Hungnes O. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007–08. Emerg Infect Dis. 2009;15 (2):155–62.
74. Esposito S, Molteni CG, Daleno C, et al. Clinical importance and impact on the households of oseltamivir-resistant seasonal A/H1N1 influenza virus in healthy children in Italy. Virol J. 2010;7:202.
75. Casalegno JS, Bouscambert-Duchamp M, Caro V, et al. Oseltamivir-resistant influenza A(H1N1) viruses in south of France, 2007/2009. Antivir Res. 2010;87(2):242–8.
76. Dharan NJ, Gubareva LV, Meyer JJ, et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA. 2009;301(10):1034–41.
77. Memoli MJ, Hrabal RJ, Hassantoufighi A, Eichelberger MC, Taubenberger JK. Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin Infect Dis. 2010;50(9):1252–1255.
78. Abed Y, Boivin G, Yoshida R, Kodama M, Hernandez JE. Parenteral peramivir treatment for oseltamivir-resistant 2009 pandemic influenza A H1N1 viruses. J Infect Dis. 2011;204(10):1641–1642; author’s reply 1642–1643.
79. Sleeman K, Sheu TG, Moore Z, et al. Influenza B viruses with mutation in the neuraminidase active site, North Carolina, USA, 2010–2011. Emerg Infect Dis. 2011;17(11):2043–2046.
80. Yen HL, McKimm-Breschkin JL, Choy KT, et al. Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population. MBio. 2013;4(4). pii: e00396-13.
81. Takashita E, Ejima M, Itoh R, et al. A community cluster of influenza A(H1N1)pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, Nov to Dec 2013. Euro Surveill. 2014;19(1). pii: 20666.
82. McKimm-Breschkin JL, Williams J, Barrett S, et al. Reduced susceptibility to all neuraminidase inhibitors of influenza H1N1 viruses with haemagglutinin mutations and mutations in non-conserved residues of the neuraminidase. J Antimicrob Chemother. 2013;68(10): 2210–2221.
83. Centers for Disease Control and Prevention [webpage on the Internet]. Highly pathogenic avian influenza A (H5N1) virus. Atlanta, GA: Centers for Disease Control and Prevention; 2014. Available from: http://www.cdc.gov/flu/avianflu/h5n1-virus.htm. Accessed February 27, 2014.
84. Lopez-Martinez I, Balish A, Barrera-Badillo G, et al. Highly pathogenic avian influenza A(H7N3) virus in poultry workers, Mexico, 2012. Emerg Infect Dis. 2013;19(9):1531–1534.
85. Centers for Disease Control and Prevention [webpage on the Internet]. Influenza A (H3N2) variant virus. Atlanta, GA: Centers for Disease Control and Prevention; 2013. Available from: http://www.cdc.gov/flu/swineflu/h3n2v-cases.htm. Accessed September 4, 2014.
86. Gao R, Cao B, Hu Y, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med. 2013;368(20):1888–1897.
87. World Health Organization. Confirmed Human Cases of Avian Influenza A(H7N9) Reported to WHO. Report 17 Data in WHO/HQ as of 08 April 2014, 17:00 GMT+1. Geneva, Switzerland: World Health Organization; 2014. Available from: http://www.who.int/influenza/human_animal_interface/influenza_h7n9/17_ReportWebH7N9Number_20140408.pdf?ua=1. Accessed January 31, 2014.
88. Muthuri SG, Myles PR, Venkatesan S, Leonardi-Bee J, Nguyen-Van-Tam JS. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009–2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients. J Infect Dis. 2013;207(4):553–563.
89. Nagai Y. A watershed in clinical outcomes of human infections with highly pathogenic H5N1 avian influenza viruses: lessons from case-management in Egypt. Rev Med Virol. 2012;22(6):351–353.
90. Uyeki TM, Cox NJ. Global concerns regarding novel influenza A (H7N9) virus infections. N Engl J Med. 2013;368(20):1862–1864.
91. Baranovich T, Burnham AJ, Marathe BM, et al. The neuraminidase inhibitor oseltamivir is effective against A/Anhui/1/2013 (H7N9) influenza virus in a mouse model of acute respiratory distress syndrome. J Infect Dis. 2014;209(9):1343–1353.
92. Gao HN, Lu HZ, Cao B, et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med. 2013;368(24):2277–2285.
93. Centers for Disease Control and Prevention [webpage on the Internet]. Interim guidance on the use of antiviral agents for the treatment of human infections with avian influenza A (H7N9) virus. Atlanta, GA: Centers for Disease Control and Prevention; 2013. Available from: http://www.cdc.gov/flu/avianflu/h7n9-antiviral-treatment.htm. Accessed September 30, 2013.
94. The Japanese Association for Infectious Diseases [webpage on the Internet]. Interim guidance – avian influenza A(H7N9) virus infections in humans. Tokyo, Japan: The Japanese Association for Infectious Diseases; 2013. Available from: http://www.kansensho.or.jp/influenza/1305_teigen.html. Accessed May 17, 2013. Japanese.
95. Centers for Disease Control and Prevention [webpage on the Internet]. Influenza antiviral medications: summary for clinicians (current for the 2013–2014 influenza season). Atlanta, GA: Centers for Disease Control and Prevention; 2013. Available from: http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm. Accessed March 21, 2014.
96. Hu Y, Lu S, Song Z, et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet. 2013;381(9885):2273–2279.
97. The Japanese Association for Infectious Diseases [webpage on the Internet]. The Japanese Association for Infectious Diseases policy statement: recommendations for influenza antiviral treatment (revised). Tokyo, Japan; 2011. Available from: http://www.kansensho.or.jp/influenza/110301soiv_teigen.html#n02. Accessed May 1, 2011. Japanese.
98. Hosoya M. [homepage on the Internet]. Available from: Administration of peramivir against severe influenza cases. http://www.jpeds.or.jp/uploads/files/2013_2014_influenza_3.pdf. Accessed January 27, 2014.
99. Kitano M, Itoh Y, Ishigaki H, et al. Efficacy of repeated intravenous administration of peramivir against highly pathogenic avian influenza A (H5N1) virus in cynomolgus macaques. Antimicrob Agents Chemother. 2014;58(8):4795–4803.
100. Jain S, Kamimoto L, Bramley AM, et al; 2009 Pandemic influenza A (H1N1) Virus Hospitalizations Investigation Team. Hospitalized patients with 2009 H1N1 influenza in the United States, Apr–Jun 2009. N Engl J Med. 2009;361(20):1935–1944.
101. Farias JA, Fernández A, Monteverde E, et al. Critically ill infants and children with influenza A (H1N1) in pediatric intensive care units in Argentina. Intensive Care Med. 2010;36(6):1015–1022.
102. Dawood FS, Jain S, Finelli L, et al; Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009;360(25): 2605–2615.
103. Yu H, Liao Q, Yuan Y, et al. Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of medical charts in China. BMJ. 2010;341:c4779.
104. Wong KK, Jain S, Blanton L, et al. Influenza-associated pediatric deaths in the United States, 2004–2012. Pediatrics. 2013;132(5):796–804.
105. Sugaya N, Tamura D, Yamazaki M, et al. Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children. Clin Infect Dis. 2008;47(3):339–345.
106. Sugaya N, Shinjoh M, Mitamura K, Takahashi T. Very low pandemic influenza A (H1N1) 2009 mortality associated with early neuraminidase inhibitor treatment in Japan: analysis of 1000 hospitalized children. J Infect. 2011;63(4):288–294.
107. Uyeki TM, Prasad R, Vukotich C, et al. Low sensitivity of rapid diagnostic test for influenza. Clin Infect Dis. 2009;48(9):e89–e92.
108. Biggerstaff M, Jhung M, Reed C, et al. Influenza-like illness, the time to seek health-care, and influenza antiviral receipt during the 2010–2011 influenza season—United States. J Infect Dis. 2014;210(4):535–544.
109. Lindegren ML, Schaffner W. Treatment with neuraminidase inhibitors for high-risk patients with influenza: why is adherence to antiviral treatment recommendations so low? J Infect Dis. Epub April 13, 2014.
110. Dominguez-Cherit G, Lapinsky SE, Macias AE et al. Critically Ill patients with 2009 influenza A(H1N1) in Mexico. JAMA. 2009;302(17):1880–1887.
111. Sugaya N. Widespread use of neuraminidase inhibitors in Japan. J Infect Chemother. 2011;17(5):595–601.
112. Beigel J, Harman LA, Collis PJ, et al. Pharmacokinetic and Safety Evaluations of Escalating Doses of Peramivir Administered Intravenously in Healthy Volunteers. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 17–20; 2007; Chicago, IL. Abstract A-1408.
113. Collis PJ, Harman LA, Kilpatrick JM, et al. A Placebo-Controlled Evaluation of the Safety and Pharmacokinetics of Multiple-Dose Intravenous Administration of Peramivir to Healthy Elderly Subjects. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 17–20; 2007; Chicago, IL. Abstract A-1409.
114. Alexander WJ, Harman LA, Collis PJ, et al. Nasal and Pharyngeal Concentrations of Peramivir Following Intramuscular and Intravenous Administration in Healthy Volunteers. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 17–20; 2007; Chicago, IL. Abstract A-1410.
115. BioCryst Pharmaceuticals. Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza. Available from: http://clinicaltrials.gov/ct2/show/NCT00419263?term=NCT00419263&rank=1#wrapper. NLM identifier: NCT00419263. Accessed September 22, 2014.
116. Atiee G, Tellier G, Collis P, et al. Virologic Analysis of Influenza Viruses after Therapy with a Single Intramuscular (IM) Dose of the Neuraminidase Inhibitor (NAI) Peramivir (PVR) Versus Placebo (PBO) in Patients with Influenza in the Outpatient (OP) Setting. Presented at: 49th Annual Meeting of the Infectious Diseases Society of America; October 20–23; 2011; Boston, MA. Abstract 1185.
117. nih.go.jp [homepage on the Internet]. Tokyo: National Institute of Infectious Diseases; 2014 [updated June 23, 2014]. http://www.nih.go.jp/niid/ja/flu-m/flutoppage/2068-flu/flu-dr/4775-flu-dr20140623.html? Accessed June 23, 2014. Japanese.
118. Centers for Disease Control and Prevention [homepage on the Internet]. Atlanta, GA: Situation Update: Summary of Weekly FluView; 2014 [updated October 10, 2014]. Available from: http://www.cdc.gov/flu/weekly/summary.htm. Accessed October 14, 2014.